ATE340580T1 - Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen - Google Patents

Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Info

Publication number: ATE340580T1
Authority: AT; Austria
Prior art keywords: sub; group; estrogen; inhibitors; formula
Prior art date: 2003-05-22

Application number

AT04734005T

Other languages

English (en)

Inventor

Bennink Herman Jan Ti Coelingh

Evert Johannes Bunschoten

Original Assignee

Pantarhei Bioscience Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-22

Filing date

2004-05-19

Publication date

2006-10-15

2004-05-19 Application filed by Pantarhei Bioscience Bv filed Critical Pantarhei Bioscience Bv

2006-10-15 Application granted granted Critical

2006-10-15 Publication of ATE340580T1 publication Critical patent/ATE340580T1/de

Links

239000000262 estrogen Substances 0.000 title abstract 2
229940011871 estrogen Drugs 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
230000002265 prevention Effects 0.000 title 1
239000000126 substance Substances 0.000 abstract 3
102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
230000001076 estrogenic effect Effects 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
239000002243 precursor Substances 0.000 abstract 2
102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 abstract 1
101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 abstract 1
101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 abstract 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010028391 Musculoskeletal Pain Diseases 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
229940046836 anti-estrogen Drugs 0.000 abstract 1
230000001833 anti-estrogenic effect Effects 0.000 abstract 1
239000003886 aromatase inhibitor Substances 0.000 abstract 1
229940046844 aromatase inhibitors Drugs 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
239000000328 estrogen antagonist Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT04734005T 2003-05-22 2004-05-19 Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen ATE340580T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03076555		2003-05-22

Publications (1)

Publication Number	Publication Date
ATE340580T1 true ATE340580T1 (de)	2006-10-15

Family

ID=33462160

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04734005T ATE340580T1 (de)	2003-05-22	2004-05-19	Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen

Country Status (13)

Country	Link
US (1)	US20060276414A1 (de)
EP (1)	EP1624878B1 (de)
CN (1)	CN100431545C (de)
AT (1)	ATE340580T1 (de)
CA (1)	CA2526338C (de)
CY (1)	CY1105766T1 (de)
DE (1)	DE602004002591T9 (de)
DK (1)	DK1624878T3 (de)
ES (1)	ES2274456T3 (de)
PL (1)	PL1624878T3 (de)
PT (1)	PT1624878E (de)
SI (1)	SI1624878T1 (de)
WO (1)	WO2004103377A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1526856B1 (de) *	2002-07-12	2008-01-02	Pantarhei Bioscience B.V.	Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
WO2008144143A1 (en) *	2007-05-14	2008-11-27	Drugtech Corporation	Endometriosis treatment
CA2698814A1 (en) *	2007-09-17	2009-03-26	Preglem S.A.	Treatment of oestrogen dependant conditions in pre-menopausal women
RS54880B1 (sr)	2011-06-01	2016-10-31	Estetra Sprl	Postupak proizvodnje intermedijarnih proizvoda estetrola
ME02585B (de)	2011-06-01	2017-06-20	Estetra Sprl	Verfahren zur herstellung von estetrolzwischenprodukten
EP2383279A1 (de)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Herstellungsverfahren für Esterol
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2782584B1 (de)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natürliche kombinierte hormonersatzformulierungen und -therapien
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
EP3701944B1 (de)	2015-06-18	2021-12-08	Estetra SRL	Schmelzende darreichungseinheit mit einer estetrolkomponente
CU24523B1 (es)	2015-06-18	2021-06-08	Estetra Sprl	Unidad de dosificación orodispersable que contiene un componente estetrol
MA44206B1 (fr)	2015-06-18	2021-04-30	Estetra Sprl	Comprimé orodispersible comprenant estetrol
LT3310345T (lt) *	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
KR20180126582A (ko)	2016-04-01	2018-11-27	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
CA3178291A1 (en)	2016-08-05	2018-04-12	Estetra Srl	Method for the management of dysmenorrhea and menstrual pain
TWI801561B (zh) *	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
EP3781171B1 (de)	2018-04-19	2022-02-09	Estetra SRL	Verbindungen und deren verwendung zur linderung von menopause-assoziierten symptomen
EP3787632B1 (de)	2018-05-02	2022-05-25	Estetra SPRL	Dosierungsschema zur behandlung von fortgeschrittenem östrogenrezeptor-positivem brustkrebs
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2834712A (en) *	1953-05-27	1958-05-13	American Home Prod	Urinary estrogen compositions and methods for preparing them
US2753290A (en) *	1953-08-06	1956-07-03	Olin Mathieson	Microbiological production of 7-and 15-hydroxy-progesterones
US3440320A (en) *	1964-06-18	1969-04-22	Mortimer D Sackler	Chelated suppository and method of using same
US3487152A (en) *	1967-02-07	1969-12-30	Hoffmann La Roche	Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
US3608075A (en) *	1969-07-28	1971-09-21	American Home Prod	Compositions and methods of treating the menopausal syndrome
YU243975A (en) *	1974-10-14	1982-06-30	Schering Ag	Process for obtaining 7-hydroxyestradiols
FR2377419A1 (fr) *	1977-01-13	1978-08-11	Roussel Uclaf	Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
US4937238A (en) *	1986-03-04	1990-06-26	The Board Of Regents Of The University Of Nebraska	Prevention of mammary carcinoma
US4762717A (en) *	1986-03-21	1988-08-09	The General Hospital Corporation	Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US5340586A (en) *	1991-04-12	1994-08-23	University Of Southern California	Methods and formulations for use in treating oophorectomized women
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
US5340585A (en) *	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
US5270172A (en) *	1991-04-26	1993-12-14	Dekk-Tek, Inc.	Method to predict tumor response to therapy
US5468736A (en) *	1993-02-25	1995-11-21	The Medical College Of Hampton Road	Hormone replacement therapy
US5811416A (en) *	1994-06-06	1998-09-22	Board Of Regents The University Of Texas System	Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate
US6613757B1 (en) *	1994-09-22	2003-09-02	Board Of Regents, The University Of Texas System	Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
US5672609A (en) *	1996-07-18	1997-09-30	Eli Lilly And Company	Pyridine compounds, intermediates compositions and methods of use
US6170058B1 (en) *	1997-12-23	2001-01-02	Arcot Systems, Inc.	Method and apparatus for cryptographically camouflaged cryptographic key storage, certification and use
US20010056068A1 (en) *	1998-03-04	2001-12-27	Kristof Chwalisz	Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
US6291456B1 (en) *	1998-12-30	2001-09-18	Signal Pharmaceuticals, Inc.	Compounds and methods for modulation of estrogen receptors
US6117446A (en) *	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents
GB0005257D0 (en) *	2000-03-03	2000-04-26	Pharmacia & Upjohn Spa	Breast cancer hormonal therapy
RU2180570C1 (ru) *	2000-09-25	2002-03-20	Писаревский Юрий Леонидович	Способ лечения болевого синдрома при дисфункциях височно-нижнечелюстного сустава у женщин
US6790979B2 (en) *	2002-04-17	2004-09-14	University Of North Carolina At Chapel Hill	Curcumin analogues and uses thereof

2004
- 2004-05-19 PL PL04734005T patent/PL1624878T3/pl unknown
- 2004-05-19 PT PT04734005T patent/PT1624878E/pt unknown
- 2004-05-19 DK DK04734005T patent/DK1624878T3/da active
- 2004-05-19 EP EP04734005A patent/EP1624878B1/de not_active Expired - Lifetime
- 2004-05-19 AT AT04734005T patent/ATE340580T1/de active
- 2004-05-19 WO PCT/NL2004/000354 patent/WO2004103377A1/en not_active Ceased
- 2004-05-19 US US10/557,549 patent/US20060276414A1/en not_active Abandoned
- 2004-05-19 ES ES04734005T patent/ES2274456T3/es not_active Expired - Lifetime
- 2004-05-19 CN CNB2004800177699A patent/CN100431545C/zh not_active Expired - Lifetime
- 2004-05-19 SI SI200430120T patent/SI1624878T1/sl unknown
- 2004-05-19 CA CA2526338A patent/CA2526338C/en not_active Expired - Lifetime
- 2004-05-19 DE DE602004002591T patent/DE602004002591T9/de active Active
2006
- 2006-11-08 CY CY20061101608T patent/CY1105766T1/el unknown

Also Published As

Publication number	Publication date
CN1816340A (zh)	2006-08-09
DE602004002591D1 (de)	2006-11-09
WO2004103377A1 (en)	2004-12-02
DK1624878T3 (da)	2007-01-08
US20060276414A1 (en)	2006-12-07
CA2526338A1 (en)	2004-12-02
SI1624878T1 (sl)	2007-02-28
EP1624878B1 (de)	2006-09-27
ES2274456T3 (es)	2007-05-16
DE602004002591T2 (de)	2007-08-09
EP1624878A1 (de)	2006-02-15
CN100431545C (zh)	2008-11-12
CY1105766T1 (el)	2011-02-02
DE602004002591T9 (de)	2008-01-03
PT1624878E (pt)	2007-01-31
CA2526338C (en)	2012-09-25
PL1624878T3 (pl)	2007-01-31

Legal Events

Date

Code

Title

Description

2007-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1624878

Country of ref document: EP

Publication	Publication Date	Title
DE602004002591D1 (de)	2006-11-09	Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
WO2002094275A8 (en)	2003-02-13	Use of estrogen compounds to increase libido in women
DK1446128T3 (da)	2007-04-02	Anvendelse af östrogenforbindelser i kombination med progestogenforbindelser i hormonsubstitutionsbehandling
NO20072286L (no)	2007-05-02	Hemming av HCV NS3-NS4A-protease
NO20071264L (no)	2007-05-15	Cyklopaminanaloger og fremgangsmater for anvendelse derav.
ATE497391T1 (de)	2011-02-15	Verfahren zur behandlung von postoperativen schmerzen durch verabreichung eines antikörpers gegen nervenwachstumsfaktor und diesen enthaltende zusammensetzungen
HUP0203304A2 (hu)	2003-02-28	Prosztatarák megelőzésére szolgáló kemoterápiás módszer és készítmény
CA2407100A1 (en)	2001-11-01	1-aroyl-piperidinyl benzamidines
MXPA05012061A (es)	2006-02-22	Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
TW200700012A (en)	2007-01-01	Oil and fat composition
DE69926400D1 (de)	2005-09-01	Zusammensetzung enthaltend insulin-sensibilisierenden wirkstoffe und inhibitoren der fruktose-1,6-bisphosphatase (fbpase) zur behandlung von diabetes
UA92348C2 (en)	2010-10-25	17b-HSD1 AND STS INHIBITORS
ATE449606T1 (de)	2009-12-15	Tetrahydroxylierte estrogen enthaltendes arzneistoffverabreichungssystem zur verwendung in hormonalen kontrazeption
WO2004006936A8 (en)	2005-03-03	Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
NO20062679L (no)	2006-08-10	Nye 17 β -hydroksysteroid-dehydrogenase-type 1-inhibitorer
ATE460413T1 (de)	2010-03-15	Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen
BRPI0403227A (pt)	2005-06-28	Composições protetoras da pele vaporizáveis
ATE340579T1 (de)	2006-10-15	Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung
DE60334711D1 (de)	2010-12-09	Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
DE60220385D1 (de)	2007-07-12	Benzimidazole zur behandlung sexueller fehlfunktionen
ATE481973T1 (de)	2010-10-15	Verfahren zur behandlung einer akuten gefässerkrankung
UA85203C2 (en)	2009-01-12	17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
DE60216239T8 (de)	2007-06-21	Verwendung von Cyclohexenon-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Dysurie
ATE451922T1 (de)	2010-01-15	Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
DE50108711D1 (de)	2006-04-06	Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz